Table 1 Primers.
From: A broad neutralizing nanobody against SARS-CoV-2 engineered from an approved drug
SARS2-N-F | TAATCAGACAAGGAACTGATTA |
SARS2-N-R | CGAAGGTGTGACTTCCATG |
SARS2-N-P | GCAAATTGTGCAATTTGCGG |
hGAPDH-F | CAGCCTCAAGATCATCAGCA |
hGAPDH-R | TGTGGTCATGAGTCCTTCCA |
hGAPDH-P | CTGCTTAGCACCCCTGGCCA |
hACE2-F | CATTGGAGCAAGTGTTGGATCTT |
hACE2-R | GAGCTAATGCATGCCATTCTCA |
hACE2-P | CTTGCAGCTACACCAGTTCCCAGGCA |
mGAPDH-F | TGCACCACCAACTGCTTAG |
mGAPDH-R | GGATGCAGGGATGATGTTC |
mGAPDH-P | CAGAAGACTGTGGATGGCCCCTC |
